| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 17 | 2019 | 253 | 5.730 |
Why?
|
| Rivaroxaban | 8 | 2020 | 26 | 3.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2021 | 1085 | 2.530 |
Why?
|
| Length of Stay | 10 | 2020 | 780 | 2.230 |
Why?
|
| Atrial Fibrillation | 6 | 2020 | 249 | 1.840 |
Why?
|
| Anticoagulants | 8 | 2021 | 356 | 1.760 |
Why?
|
| Warfarin | 6 | 2018 | 93 | 1.650 |
Why?
|
| Hospitalization | 10 | 2020 | 978 | 1.520 |
Why?
|
| Neoplasms | 6 | 2019 | 1667 | 1.500 |
Why?
|
| Social Determinants of Health | 2 | 2022 | 96 | 1.410 |
Why?
|
| Retrospective Studies | 33 | 2022 | 7277 | 1.370 |
Why?
|
| Residence Characteristics | 3 | 2020 | 252 | 1.270 |
Why?
|
| Hospital Mortality | 8 | 2019 | 384 | 1.240 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 504 | 1.150 |
Why?
|
| Medication Adherence | 4 | 2021 | 335 | 1.150 |
Why?
|
| Aged | 34 | 2021 | 14862 | 1.130 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 940 | 1.120 |
Why?
|
| Patient Readmission | 5 | 2019 | 267 | 1.110 |
Why?
|
| Thrombolytic Therapy | 2 | 2019 | 233 | 1.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2021 | 212 | 1.100 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 694 | 1.050 |
Why?
|
| Emergency Service, Hospital | 8 | 2020 | 711 | 1.040 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 839 | 1.010 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 1851 | 0.970 |
Why?
|
| Hemorrhage | 7 | 2021 | 328 | 0.960 |
Why?
|
| Humans | 64 | 2022 | 68618 | 0.950 |
Why?
|
| Male | 43 | 2021 | 37321 | 0.940 |
Why?
|
| Female | 43 | 2021 | 38074 | 0.930 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2020 | 3 | 0.920 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 4848 | 0.900 |
Why?
|
| Inappropriate Prescribing | 2 | 2020 | 27 | 0.890 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 365 | 0.870 |
Why?
|
| Students, Pharmacy | 2 | 2021 | 79 | 0.860 |
Why?
|
| United States | 18 | 2022 | 7367 | 0.850 |
Why?
|
| Insurance Claim Review | 3 | 2018 | 39 | 0.850 |
Why?
|
| Cholesterol, LDL | 2 | 2020 | 161 | 0.840 |
Why?
|
| Heart Failure | 3 | 2020 | 1180 | 0.800 |
Why?
|
| Pharmacy Residencies | 1 | 2021 | 18 | 0.760 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2021 | 18 | 0.760 |
Why?
|
| Risk Assessment | 13 | 2020 | 2007 | 0.760 |
Why?
|
| Health Status Disparities | 2 | 2022 | 326 | 0.730 |
Why?
|
| Patient Admission | 3 | 2019 | 99 | 0.710 |
Why?
|
| Dabigatran | 1 | 2020 | 35 | 0.710 |
Why?
|
| Veterans Health | 1 | 2020 | 62 | 0.700 |
Why?
|
| Ambulatory Care | 3 | 2018 | 340 | 0.700 |
Why?
|
| Heparin | 2 | 2021 | 205 | 0.700 |
Why?
|
| Dyslipidemias | 1 | 2020 | 98 | 0.680 |
Why?
|
| Accidental Falls | 1 | 2020 | 84 | 0.680 |
Why?
|
| Middle Aged | 25 | 2021 | 21147 | 0.650 |
Why?
|
| Ranolazine | 1 | 2018 | 2 | 0.650 |
Why?
|
| Diuretics | 1 | 2019 | 97 | 0.640 |
Why?
|
| Angina, Stable | 1 | 2018 | 13 | 0.640 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 82 | 0.640 |
Why?
|
| Benzazepines | 2 | 2016 | 104 | 0.640 |
Why?
|
| Rural Population | 1 | 2021 | 398 | 0.630 |
Why?
|
| Prognosis | 8 | 2020 | 2093 | 0.620 |
Why?
|
| Veterans | 3 | 2021 | 904 | 0.610 |
Why?
|
| Outpatients | 1 | 2018 | 127 | 0.610 |
Why?
|
| Glucosides | 1 | 2017 | 16 | 0.600 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 125 | 0.590 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 62 | 0.580 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 198 | 0.560 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2016 | 17 | 0.550 |
Why?
|
| Stroke Volume | 2 | 2016 | 586 | 0.550 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 203 | 0.540 |
Why?
|
| Hospital Costs | 1 | 2017 | 117 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 504 | 0.510 |
Why?
|
| Internship and Residency | 1 | 2021 | 596 | 0.510 |
Why?
|
| Treatment Outcome | 11 | 2019 | 7029 | 0.500 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2022 | 56 | 0.500 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 171 | 0.490 |
Why?
|
| Heart Rate | 2 | 2019 | 568 | 0.490 |
Why?
|
| Inpatients | 1 | 2016 | 208 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 468 | 0.480 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 185 | 0.470 |
Why?
|
| Adult | 18 | 2021 | 21403 | 0.470 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 240 | 0.460 |
Why?
|
| Venous Thromboembolism | 4 | 2021 | 117 | 0.460 |
Why?
|
| Stroke | 4 | 2018 | 2163 | 0.440 |
Why?
|
| Costs and Cost Analysis | 3 | 2020 | 193 | 0.430 |
Why?
|
| Risk Factors | 8 | 2019 | 5731 | 0.430 |
Why?
|
| Observation | 3 | 2017 | 30 | 0.420 |
Why?
|
| Cohort Studies | 6 | 2021 | 2358 | 0.410 |
Why?
|
| Brain Ischemia | 1 | 2018 | 665 | 0.410 |
Why?
|
| Asthma | 3 | 2022 | 345 | 0.390 |
Why?
|
| Comorbidity | 4 | 2019 | 1426 | 0.380 |
Why?
|
| Medicare | 4 | 2021 | 319 | 0.370 |
Why?
|
| Hypoglycemic Agents | 4 | 2021 | 362 | 0.370 |
Why?
|
| Glomerular Filtration Rate | 3 | 2020 | 274 | 0.360 |
Why?
|
| Quality of Life | 1 | 2018 | 1515 | 0.350 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2022 | 186 | 0.330 |
Why?
|
| Acute Disease | 3 | 2019 | 658 | 0.320 |
Why?
|
| Insulin | 3 | 2020 | 619 | 0.310 |
Why?
|
| Factor Xa Inhibitors | 3 | 2018 | 43 | 0.310 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 567 | 0.290 |
Why?
|
| Prospective Studies | 4 | 2018 | 3705 | 0.280 |
Why?
|
| Administration, Oral | 2 | 2018 | 411 | 0.270 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.240 |
Why?
|
| Health Care Costs | 2 | 2016 | 346 | 0.220 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1054 | 0.210 |
Why?
|
| Pharmacists | 2 | 2021 | 125 | 0.210 |
Why?
|
| Skin Diseases, Infectious | 1 | 2021 | 16 | 0.200 |
Why?
|
| China | 1 | 2021 | 138 | 0.190 |
Why?
|
| Time Factors | 2 | 2020 | 4655 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 92 | 0.190 |
Why?
|
| Venoms | 1 | 2021 | 6 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1745 | 0.190 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2021 | 17 | 0.190 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 20 | 0.190 |
Why?
|
| Glucagon-Like Peptides | 1 | 2021 | 15 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2019 | 155 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 202 | 0.190 |
Why?
|
| Liraglutide | 1 | 2021 | 18 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 91 | 0.190 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 92 | 0.190 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2021 | 41 | 0.190 |
Why?
|
| Urban Health | 1 | 2020 | 49 | 0.180 |
Why?
|
| Polypharmacy | 1 | 2020 | 31 | 0.180 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 156 | 0.180 |
Why?
|
| Rural Health | 1 | 2020 | 66 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 245 | 0.170 |
Why?
|
| Diltiazem | 1 | 2019 | 26 | 0.170 |
Why?
|
| Anilides | 1 | 2019 | 16 | 0.170 |
Why?
|
| Data Anonymization | 1 | 2019 | 9 | 0.170 |
Why?
|
| Blood Glucose | 2 | 2020 | 631 | 0.170 |
Why?
|
| Hyperkalemia | 1 | 2019 | 21 | 0.170 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 14 | 0.170 |
Why?
|
| Hypoalbuminemia | 1 | 2019 | 9 | 0.170 |
Why?
|
| Health Policy | 1 | 2021 | 221 | 0.170 |
Why?
|
| Pharmacokinetics | 1 | 2019 | 14 | 0.170 |
Why?
|
| Acute Chest Syndrome | 1 | 2019 | 19 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 138 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 164 | 0.160 |
Why?
|
| Proteinuria | 1 | 2019 | 136 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2019 | 48 | 0.160 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 114 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2019 | 104 | 0.160 |
Why?
|
| Central Nervous System Agents | 1 | 2019 | 37 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2020 | 158 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2019 | 622 | 0.160 |
Why?
|
| Neurotransmitter Agents | 1 | 2019 | 102 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 110 | 0.160 |
Why?
|
| Valproic Acid | 1 | 2019 | 93 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 88 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 60 | 0.160 |
Why?
|
| Education, Distance | 1 | 2018 | 34 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 206 | 0.150 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 92 | 0.150 |
Why?
|
| Markov Chains | 1 | 2018 | 133 | 0.150 |
Why?
|
| Peptides | 1 | 2021 | 455 | 0.150 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 54 | 0.150 |
Why?
|
| Pyridines | 1 | 2019 | 261 | 0.150 |
Why?
|
| Body Weight | 1 | 2019 | 554 | 0.150 |
Why?
|
| Blood Coagulation | 1 | 2018 | 123 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 106 | 0.150 |
Why?
|
| Patient Selection | 1 | 2021 | 592 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 130 | 0.150 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 49 | 0.140 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 90 | 0.140 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 7 | 0.140 |
Why?
|
| Drug Costs | 1 | 2017 | 87 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 42 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.140 |
Why?
|
| Graft Survival | 1 | 2019 | 465 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2016 | 19 | 0.140 |
Why?
|
| Resource Allocation | 1 | 2016 | 35 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 1026 | 0.130 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 16 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 191 | 0.130 |
Why?
|
| Angina Pectoris | 1 | 2016 | 61 | 0.130 |
Why?
|
| Angiography | 1 | 2016 | 194 | 0.130 |
Why?
|
| Administration, Intravenous | 3 | 2020 | 89 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 267 | 0.130 |
Why?
|
| Aminobutyrates | 1 | 2015 | 94 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 364 | 0.130 |
Why?
|
| Administration, Inhalation | 3 | 2022 | 187 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 450 | 0.120 |
Why?
|
| Tetrazoles | 1 | 2015 | 160 | 0.120 |
Why?
|
| Registries | 1 | 2018 | 733 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1593 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2016 | 737 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2019 | 659 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2800 | 0.110 |
Why?
|
| Adolescent | 4 | 2021 | 8912 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 445 | 0.090 |
Why?
|
| Budesonide | 2 | 2022 | 10 | 0.090 |
Why?
|
| Incidence | 3 | 2021 | 1603 | 0.090 |
Why?
|
| Waiting Lists | 2 | 2021 | 104 | 0.090 |
Why?
|
| Formoterol Fumarate | 2 | 2022 | 25 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 807 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 696 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2022 | 304 | 0.080 |
Why?
|
| Maintenance Chemotherapy | 2 | 2018 | 10 | 0.080 |
Why?
|
| Bias | 2 | 2018 | 148 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 307 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2324 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 649 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2019 | 374 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1553 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 1864 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1753 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 848 | 0.060 |
Why?
|
| Ethanolamines | 1 | 2022 | 33 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2279 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 145 | 0.050 |
Why?
|
| Vancomycin | 1 | 2021 | 60 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2022 | 150 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2021 | 174 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2021 | 199 | 0.050 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 147 | 0.040 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 206 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 281 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2019 | 13 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 85 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 62 | 0.040 |
Why?
|
| Potassium | 1 | 2019 | 168 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 468 | 0.040 |
Why?
|
| Albuminuria | 1 | 2019 | 171 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 123 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 120 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 170 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 5717 | 0.040 |
Why?
|
| Education, Pharmacy | 1 | 2018 | 102 | 0.040 |
Why?
|
| Professional Role | 1 | 2017 | 80 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 109 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 392 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2018 | 254 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 2016 | 15 | 0.030 |
Why?
|
| Immune System Diseases | 1 | 2016 | 12 | 0.030 |
Why?
|
| Vital Signs | 1 | 2016 | 19 | 0.030 |
Why?
|
| Neprilysin | 1 | 2015 | 55 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 390 | 0.030 |
Why?
|
| Valsartan | 1 | 2015 | 99 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 931 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2015 | 184 | 0.030 |
Why?
|
| Kidney | 1 | 2019 | 945 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 575 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1465 | 0.030 |
Why?
|
| Physicians | 1 | 2017 | 324 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 458 | 0.030 |
Why?
|
| South Carolina | 1 | 2018 | 2752 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1330 | 0.020 |
Why?
|